New insights regarding the potential of the pronucleotide approach in antiviral chemotherapy

• Autorzy: Gosselin G. , Girardet J.L. , Perigaud C. , Benzaria S. , Lefebvre I. , Schlienger N. , Pompon A. , Imbach J.L.
• Języki publikacji: EN

Abstrakty

EN

The rationale for a pronucleotide approach based on the use of phosphotriesters which incorporate enzyme-mediated bio-labile protection is discussed in detail. Among the studied bio-labile phosphate protecting groups, the S-acyl-2-thioethyl (SATF.) groups appeared the most promising as exemplified in cell culture systems in the case of the pronucleotides of 3'-a7.ido-3'-deoxythymidine, 2',3'-didehydro- -3-deoxythymidine, 2'„3-dideoxyadenosine and acyclovir. 7m vivo implementations of such bis(SATE) pronucleotides have been planned for future animal studies.

Słowa kluczowe

EN

nucleotide prodrug; nucleoside analogue; antiviral chemotherapy; antiviral activity

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 1996
• Tom: 43
• Numer: 1
• Opis fizyczny: p.195-208

Twórcy

autor

Gosselin G.

• Universite de Monpellier II, case courrier 008, Place Eugene Bataillon, 34095 Montpellier Cedex 05, France

autor

Girardet J.L.

autor

Perigaud C.

autor

Benzaria S.

autor

Lefebvre I.

autor

Schlienger N.

autor

Pompon A.

autor

Imbach J.L.

Bibliografia

• 1. Périgaud.C, Gosselin, G. & Imbach, J.-L. (1992) Nucleoside analogues as chemotherapeutic agents: a review. Nucleosides & Nucleotides 11. 903-945.
• 2. Kinchington, D. & Golfdthorpe, S. (1995) Current antiviral agents. Part 1 — Herpes viruses, hepatitis viruses and respiratory viruses. Int. Antiviral News 3,57-61.
• 3. Goldthorpe, S., Kinchington, D. & Lovelidge, L. (1995) Current antiviral agents. Part 2 — Human immunodeficiency viruses. Int. Antiviral News 3, 92-98.
• 4. Sommadossi, J.-P. (1993) Nucleoside analogs: similarities and differences. Clin. Jnfec. Dis. 16 (Suppl 1), S7-S15.
• 5. Zelphati, O., Degols, G., Loughrey, H., Leser- man, L., Pompon, A., Puech, F., Maggio, A.-F., Imbach, J.-L. & Gosselin, G. (1993) Inhibition of HIV-1 replication in cultured cells with phos- phorylated dideoxvuridine derivatives encap­sulated in immunoliposomes. Antiviral Res. 21, 181-195.
• 6. Alexander, P. & Holy, A. (1994) Prodrugs of analogs of nucleic acid components. Collect. Czech. Chem. Commun. 59, 2127-2165.
• 7. Jones, R.J. & Bischofberger. N. (1995) Mini- review: nucleotide prodrugs. Antiviral Res. 27, 1-17.
• 8. Perigaud, C., Girardet, J.-L., Gosselin, G. & Imbach, J.-L. (1995) Comments on nucleotide delivery forms; in Advances in Antiviral Drug Design (De Clercq, H. ed.) vol. 2. pp. 142-172.
• 9. Farquhar, D., Khan, S., Srivastva, D.N. & Saun ders, P.P. (1994) Synthesis and antitumor evalua­tion of bisi(pivalovloxy)methyll 2'-deoxy-5- fluorouridine 5'-monophosphate (FdUMP): A strategy to introduce nucleotides into cells. /. Med. Chem. 37, 3902-3909. and references cited therein.
• 10. Pompon, A., Lefebvre, 1., Imbach, J.-L., Kahn, S. & Farquhar, D. (1994) Decomposition pathways of the mono-and bis(pivaloyloxymetnyl) esters of azidothymidine 5-monophosphate in cell extract and in tissue culture medium: an application of the "on-line ISRP-cleaning" HPLC technique. Antiviral Chem. Chemother. 5, 91-98.
• 11. Perigaud, C., Gosselin, G., Lefebvre, I.,Girardet, J.-L, Benzaria.S.. Barber. 1. & Imbach, J.-L. (1993) Rational design for cytosolic delivery of nucleoside monophosphates: "SATE" and "DTE" as enzyme-labile transient phosphate protecting groups. Btoorg. Med. Client. Lett. 3, 2521-2526.
• 12. Sastrv, K.J., Nehete. P.N., Khan, S., Plunkett. W., Arlinghaus, R.B. & Farquhar. D. (1992) A new strategy for the chemotherapy of acquired im­munodeficiency syndrome: membrane perme­able dideoxyuridine monophosphate analo­gues as potent inhibitors of human immuno­deficiency virus infection. Mol. Pharmacol. 41. 441-445.
• 13. Gosselin, G.& Imbach, J.-L.( 1993) The anti-HIV nucleoside phosphotriester approach: controversial comments and complementary data. Int. Antiviral News 1,100-102.
• 14. Puech, F., Gosselin, G.. Lefebvre, I., Pompon, A., Aubertin, A.-M., Kirn, A. & Imbach, J.-L. (1993) Intracellular delivery of nucleoside monophos­phates through a reductase-mediated activation process. Antiviral Res. 22,155-174.
• 15. Lefebvre, L, Perigaud, C., Pompon, A., Auber­tin, A.-M., Girardet, J.-L, Kirn, A., Gosselin, G. & Imbach, J.-L. (1995) Mononucleoside phos­photriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3'-azido-2',3'-dide- oxvthymidine 5'-monophosphate. /. Med. Chem. 38,' 3941-3950.
• 16. Starrett, J.E., Jr., Tortolani, D.R., Hitchcock, M.J.M., Martin, J.C. & Mansuri, M M. (1992) Synthesis and in vitro evaluation of a phos- phonate prodrug: bis(pivaloyloxymethvl) 9-(2-phosphonvlmethoxyethvl)adenine. Anti­viral Res. 19, 267-273.
• 17. Srinivas, R.V., Robbins, B.L., Connelly, M.C., Gong, Y.-F., Bischofberger, N. & Friedland, A. (1993) Metabolism and in vitro antiretroviral activities of bis(pivalovloxymethyl) prodrugs of acyclic nucleoside phosphonates. Aniimicrob. Agents Chemother. 37, 2247-2250.
• 18. Srinivas, R.V., Robbins, B.L, Connelly, M.C., Gong, Y.-F., Bischofberger, N. & Friedland, A. (1994) Pivalovloxymethyl esters of acyclic nucleoside phosphonates. Int. Antiviral News 2. 53-55.
• 19. Starrett, J.E., Jr., Tortolani, D.R., Russell, J., Hitchcock, M.J.M., Whiterock, V., Martin, J.C. & Mansuri, M.M. (1994) Synthesis, oral bio­availability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonylmethoxv)ethvI Jadenine (PMEA). j. Med. Chem. 37. 1857-1864.
• 20. Cundy, K.C., Fishback, J.A., Shaw, ).-?., Lee. M.L., Soike, K.F., Visor. G.C. & Lee. W.A. (1994) Oral bioavailability of the antiretroviral agent 9-(2-phosphonvlmethoxyethyl)adenine (PMF.A) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkevs. Pharmaceut. Res. 11,839- -843.
• 21. Riddler. S.A., Anderson. R.E. & Mellors, J.W. (1995) Antiretroviral activity of stavudine (2',3'-didehydro-3-deoxvthymidine, D4T). Anti­viral Res. 27,189-203.
• 22. Girardet, J.-L., Perigaud, C., Aubertin, A.-M., Gosselin. G., Kirn, A. & Imbach, J.-L. (1995) Increase of the anti-HIV activity of D4T in human T-cell cultures by the use of the SATE pronucleotideapproach. Bioorg. Med. Chem. Lett. 5,2981-2984.
• 23. Johnson, M.A., Ahluwalia, G., Connelly, M.C., Cooney, D.A., Broder,S., Johns, D.G.& Fridland, A. (1988) Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxy- adenosine in human Ivmphoid cells. /. Biol. Chem. 263.15354-15357.'
• 24. Faulds, D. & Brogden, R.N. (1992) Didanosine. Drugs 44,94-116.
• 25. Nair. V. & Sells, T.B. (1992) Interpretation of the roles of adenylosuccinate lyase and of AMP deaminase in the anti-HIV activity of 2',3'-dide- oxyadenosine and 2',3'-dideoxyinosine. Bio- chi'm. Biophys. Acta 1119, 201-204.'
• 26. Benzaria. S., Girardet, J.-L, Perigaud, C., Au­bertin, A.-M., Pelicano, H., Maury, G., Gosselin. G., Kirn. A. & Imbach, J.-L (1994) The SATE pronucleolide derivative of ddA: a more potent HIV inhibitor than A/T. Nucleic Acids Symp. Series 31, 129-130.
• 27. Perigaud, C., Aubertin, A.-M., Benzaria, 5., Pelicano, H.,Girardet, J.-L., Maury,G.,Gosselin, G., Kirn, A. & Imbach, J.-L. (1994) Equal inhi­bition o!" the replication of human immuno­deficiency virus in human T-cell culture by dd A bis(SATF.)phosphotriester and 3'-azido-2',3'- dideoxythymidine. Biochcm. Pharmacol 48, II- -14.
• 28. Baker, D.A. (ed.) (1990) Acyclovir for herpesvirus infectious therapy. Dekker Publications, New- York.
• 29. YVagstaff, A.J., Faulds, D. & Goa, K.L. (1994) Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47, 153-205.
• 30. Martin,J.C., McGee, D.P.C.,Jeffrey,G.A.,I lobbs, D.W., Smee, D.F., Matthews, T.R. & Verheyden, J.P.I 1. (1986) Synthesis and anti-herpes-virus activity of acyclic 2'-deoxyguanosine analogues related to 9-1(1,3-dihydroxy-2-propoxy)me- thvllguanine. J. Med. Chew. 29,1384 1389'.
• 31. Wu, S., Liu, X.. Solorzano, M.M., Kwock. R. & Avramis, V.l. (1995) Development of zidovu­dine (AZT) resistance in Jurkat I cells is asso­ciated with decreased expression of the thymi­dine kinase (TK) gene and hypermethylation of the 5' end of human TK gene. J. Acquired Inmiune-Defic. Syndromes Hum. Retrovirol. 8,1-9.